Rexulti, Rxulti (brexpiprazole) is a small molecule pharmaceutical. Brexpiprazole was first approved as Rexulti on 2015-07-10. It is used to treat major depressive disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat schizophrenia. It is known to target D(2) dopamine receptor. Rexulti's patents are valid until 2032-10-12 (FDA).
|Indication||major depressive disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders|
|Drug Class||Antiulcer agents (benzimidazole derivatives)|